Key personnel within the company
Possess core capabilities, including R&D technology for new drug development, commercialization, licensing, and overseas business
CEO
Chanho Park
- CEO of Remedi Co., Ltd.
- MBD Co., Ltd. Senior Researcher (BD & PM)
- Chief researcher, Hypoxic Targeted Disease Research Center
- Seoul National University, Molecular Medicine and Biopharmaceuticals, MS
- University of Washington, Chemistry, BS
CTO
Seongmin Cho
- Director of Remedi Co., Ltd. / Chief Technology Officer
- Team Leader, Medical Bioconvergence Research Group
- Seoul National University, Molecular Medicine and Biopharmaceuticals, PhD
- University of Washington, Biochemistry, BS
COO
Seungchan Moon
- Current Quality Assurance Director at Remedy Co., Ltd.
- Director of BioNT Co., Ltd.
- MBD Co., Ltd. Chief Researcher
- Ultra V Co., Ltd. Process Development Team Leader
- Medytox Co., Ltd.
- Ministry of Pharmaceutical Industry, Korea Vaccine Co., Ltd.
Management and technology advisory group
Establishing an advisory organization with outstanding management capabilities and technical performance
Management and Investment Advisory
Hoyeon Cho
- Former Chairman/Founder of CTC Bio Co., Ltd.
- Former CEO of CTC Bio Co., Ltd.
- Seoul National University Executive Program (AMP)
- Bachelor's degree from Seoul National University
Advising on new drug development
Jinseo Park
- Dean of Hallym University Graduate School
- Havard Medical School (Postdoc)
- University of Alabama, Microbiology PhD
- KAIST, Biological Engineering Master degree
- Bachelor's degree from Yonsei University
Advising on new drug development
Sooyoung Choi
- Research Chair Professor, Hallym University
- President of the Korean Society for Biochemistry and Molecular Biology
- Regular member of Korea Academy of Science and Technology
- Former President of the Korean Neuroscience Society
- University of California, Berkeley (Postdoc)
- University of Tennessee, Knoxville PhD
- Yonsei University Bachelor’s degree, Master’s degree